Actively Recruiting

Age: 18Years - 80Years
All Genders
ID07313579

Observational Prospective Cohort Study on Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer

Led by Ukrainian Society of Clinical Oncology · Updated on 2026-01-13

200

Participants Needed

1

Research Sites

260 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating the outcomes of combining hyperthermic intraperitoneal chemoperfusion (HIPEC) with curative-intent gastrectomy in patients who have resectable locally-advanced and limited-metastatic gastric cancer with a low peritoneal cancer index. This study addresses the challenge that surgery combined with systemic chemotherapy or immunotherapy may not always remove microscopic cancer deposits or prevent peritoneal spread, especially in T4 tumors or those with positive peritoneal washings. The goal is to reduce the risk of peritoneal progression by adding HIPEC after surgery. Participants will undergo curative-intent gastrectomy followed immediately by a single dose of HIPEC during the same operation. The HIPEC procedure uses mitomycin C and cisplatin administered according to a standardized protocol. The study groups include patients with T4a or T4b tumors or positive peritoneal cytology, and those with low peritoneal cancer index (less than 7) who receive cytoreduction of visible peritoneal nodules before HIPEC. During the study, participants will be monitored for up to five years to assess the rate of peritoneal recurrence as the primary outcome. Secondary outcomes include distant recurrence rates, complications related to intraperitoneal chemotherapy and surgery within 30 days, overall survival, relapse-free survival over five years, and treatment-related quality of life measured six months after treatment. The study involves follow-up assessments and questionnaires to evaluate these outcomes comprehensively.

CONDITIONS

Brief Title

Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 80 years
  • Histologically confirmed gastric adenocarcinoma
  • ECOG performance status 0 or 1
  • Written consent to participate in the study
  • Medically and technically operable gastric tumor
  • Tumors classified as T4a or T4b with any peritoneal cytology status
  • Cytologically positive peritoneal washings with any T and N criteria
  • Adequate blood, liver, and kidney function (specific lab value limits)
Not Eligible

You will not qualify if you...

  • Pregnancy or breastfeeding
  • ECOG performance status 2 to 4
  • Presence of other active cancers
  • Known hypersensitivity to mitomycin or cisplatin
  • Uncontrolled chronic diseases
  • History of other malignancies (except basal cell skin carcinoma) within the last five years
  • Metastases beyond regional or peritoneal areas
  • Psychiatric illness or social situations affecting study compliance
  • Refusal to participate in the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Surgery and Immediate Post-operative Care

Duration - Hospital stay duration following surgery

Participants undergo curative-intent gastrectomy followed by a single dose of hyperthermic intraperitoneal chemotherapy (HIPEC) during the same surgery session.

1 surgical procedure with immediate post-operative care

Post-operative Follow-up

Duration - 30 days after surgery and chemotherapy

Participants are monitored for chemotherapy and surgery-related complications and recovery during the 30 days post-treatment.

Approximately 6 post-operative visits

Long-term Monitoring

Duration - Up to 5 years

Participants are followed up to monitor peritoneal and distant recurrence, survival, and quality of life for up to 5 years after treatment.

Regular follow-up visits according to clinical practice

Trial Site Locations

Total: 1 location

1

National Cancer Institute (NCI)

Kyiv, Ukraine

Actively Recruiting

Loading map...

Research Team

O

Oleksiy Dobrzhanskyi, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

A Noninvasive and Screening miRNA Signature for Gastrointest...

Hepatocellular Carcinoma (HCC)

Actively Recruiting

1 location

An Open, Multicenter, Phase I Study on the Safety, Efficacy,...

Liver Cancer (Locally Advanced or Metastatic)

Actively Recruiting

1 location

Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for ...

Gastric Cancer (GC)

Actively Recruiting

5 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here